# Development of  a novel class of immunotherapeutic antibody for metastatic prostate cancer

> **NIH NIH R44** · CANCURE, LLC · 2020 · $681,039

## Abstract

Abstract
The overarching goal of this application is to development a novel immunotherapy for treatment of metastatic
prostate cancer (mPC), a lethal with limited treatment options. Immunotherapy has significantly improved survival
in patients with a variety of solid tumors, however it has only presented limited efficacy in metastatic prostate
cancer patients. Thus, there is an unmet need to develop effective immunotherapies for mPC. Based on the
findings that metastatic prostate tumor cells convert the stress-induced immune stimulatory cell surface
molecule, the MHC I Chain related molecule (MIC), to a highly immune suppressive soluble MIC (sMIC).
CanCure has developed a first-in-class sMIC-targeting monoclonal antibody (mAb) B10G5 that has
demonstrated remarkable efficacy in eliminating prostate metastatic as a single agent in preclinical models.
When used in combination, B10G5 synergizes with immune checkpoint blockade therapy and eliminates immune
checkpoint therapy-induced colon toxicity. We show that B10G5 confers its therapeutic efficacy through two
defined mechanisms of action. CanCure has formulated the B10G5 mAb for human use (designated and
huB10G5) and tested the safety of huB10G5 in pilot toxicity study in non-human primates (NHP). HuB10G5 is
ready for IND-enabling studies. To achieve our goal, CanCure proposes two specific Aims: 1) Determine
therapeutic efficacy of B10G5 with frontline AR-targeting therapy for mPC; 2) Conduct pre-clinical IND-enabling
GLP production and toxicology study. The outcome of proposed study would define the path and provide a strong
scientific rationale on how to translate our new therapy into early clinical trials.
 .

## Key facts

- **NIH application ID:** 10017200
- **Project number:** 5R44CA247503-02
- **Recipient organization:** CANCURE, LLC
- **Principal Investigator:** GRANT H RISDON
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $681,039
- **Award type:** 5
- **Project period:** 2019-09-12 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10017200

## Citation

> US National Institutes of Health, RePORTER application 10017200, Development of  a novel class of immunotherapeutic antibody for metastatic prostate cancer (5R44CA247503-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10017200. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*